BL vs REGN · P/E 64, rev $653.3M vs P/E 14, rev $14.34B
Blackline Inc (BL) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Blackline Inc (BL) is a software - application company listed on NASDAQ.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported BL revenue for 2024-12-31 was $653.3M. Net income was $167.8M. Revenue was up 10.7% from 2023-12-31 to 2024-12-31. BL currently screens at market cap $1.57B and trailing P/E 63.9.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
BL currently screens at market cap $1.57B and trailing P/E 63.9. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the BL and REGN stock pages for the full models.
Not investment advice.